Zelda Therapeutics has been formed to bring together some of the world's leading researchers and clinicians active in the study and use of medicinal cannabis to treat a variety of ailments.
In collaboration with Curtin University in Perth, Western Australia, Zelira Therapeutics is testing a range of the company’s cannabinoid-based formulations and protocols against Curtin’s suite of in vitro pancreatic cancer models, as well as against human pancreatic cell cancer lines grown in the laboratory.
Working with researchers at Complutense University in Spain, Zelira Therapeutics continues to generate positive research results from its breast cancer research program.
Working with researchers at the Telethon Kids Institute (TKI) at Perth Children’s Hospital (PCH) in Western Australia in a study of paediatric brain cancer, Zelira Therapeutics has demonstrated that two chemicals naturally occurring in the cannabis plant, tetrahydrocannabinol (THC) and cannabidiol (CBD), have some anti-cancer effects. The next phase in this brain cancer research is to compare the results from the company’s whole plant extracts versus the pure THC and pure CBD results: this research is ongoing.
DIABETES RELATED COGNITIVE DECLINE
Working with researchers at the Curtin Health Innovation Research Institute at Curtin University in Perth, Zelira Therapeutics is examining the potential for cannabinoids to treat diabetes-associated cognitive decline. One of the complications of diabetes is damage to blood vessels in the brain, which is associated with cognitive decline, which can lead to dementia and other conditions. Zelira Therapeutics is testing its cannabinoid formulations on validated animal models of diabetic cognitive decline developed by Curtin University. This research is ongoing.
Cannabinoid-based medication has the potential to provide an alternative treatment for chronic pain.
The usual treatment for chronic pain is prescription opioids, but these drugs can have serious side effects, including physical dependence. The epidemic of opioid addiction has become a global crisis, with a high mortality and growing number of people being treated for dependence on painkillers. The rate of accidental deaths due to opioids has doubled for Australians aged 35 to 44 since 2007, with more than two-thirds of these deaths due to pharmaceutical opioids.
Zelira Therapeutics is conducting Australia’s first medicinal cannabis trial targeting insomnia.
Working with researchers at the Children’s Hospital of Philadelphia (CHOP) in the US, Zelira Therapeutics is conducting an observational trial aimed at paediatric autism, studying the use of cannabinoid-based treatments in controlled clinical settings. The ultimate goal of the trial is to identify cannabinoid-based compounds that may show effectiveness in the treatment of paediatric autism. The study could provide a platform for possible future clinical trials.
Last updated 13th February 2020
Mr. Imasogie is the Co-Founder and Senior Managing Partner of PIPV Capital with over 30 years of experience in the fields of law, finance and business management, healthcare and the pharmaceutical industry. Prior to co-founding PIPV Capital, Osagie conceptualized and established GlaxoSmithKline Ventures in which he led his team in investing GSK R&D non-progressed assets into various companies and/or as the basis of starting new companies. Prior to this role within GSK, Osagie was a Vice President for Product Development Strategy at SmithKline Beecham.
Prior to this role at SmithKline, he was the Founding Senior Vice President for Business Development and General Counsel at Endo Pharmaceuticals. He also previously served as a DuPont Merck Vice President for International Sales and Marketing and General Counsel to DuPont Merck’s International, Manufacturing and Generic Drug Divisions. Osagie has been a serial entrepreneur and has been founder and former CEO and/or Chairman of multiple life sciences companies, including Ilera Healthcare, iCeutica, Churchill Pharmaceuticals, Ception Therapeutics and Trigenesis Therapeutics. Osagie has also been a Corporate Finance Partner in Price Waterhouse and a practicing attorney in a major US Law Firm.
Osagie is active in charitable and community pursuits and serves as a member of the Board of the Philadelphia Orchestra and the Philadelphia Museum of Art. Osagie is an Adjunct Professor at the University of Pennsylvania Law School and also serves on the Law School’s Board of Overseers. In addition, he is a member of the Board of Trustees of the University of Pennsylvania and serves as the Chairman of the Budget & Finance Committee in addition to being a member of the Executive Committee. Osagie is a member of the New York State Bar.
Mr Karelis graduated from The University of Western Australia with Bachelors and Honours in Science majoring in Biochemistry and Microbiology as well as a Masters in Business Administration. He is a Fellow of the Financial Services Institute of Australia, a Fellow of the Australian Institute of Company Directors and has qualified as a Chartered Financial Analyst (CFA) from the CFA Institute in the United States.
He has in over 25 years’ diversified experience in the financial services sector including fundamental analysis, funds management and private equity investing and has acted as a director on several public and private companies in Australia, Singapore and the United Kingdom. Harry resides in Australia.
Mr Peterson is a director, major shareholder and Head of Corporate of boutique stock broking and corporate advisory firm CPS Capital. He has more than 21 years’ experience in the financial advisory sector, which he obtained by working in both local and international stockbroking companies such as Patersons, Tolhurst and Merrill Lynch.
Mr Peterson specialises in corporate structuring, capital raisings, corporate and strategic advice to small and medium size companies and reverse takeovers. He holds a Bachelor of Commerce degree from Curtin University and a Graduate Diploma of Finance from FINSIA (Financial Services Institute of Australia)/SDIA (Securities & Derivatives Institute of Australia). He resides in Australia.
Dr Richard Hopkins
Managing Director ex USA
Dr Hopkins is an experienced bio-pharmaceutical executive with over 11 years in corporate leadership roles with public biotechnology companies. He has an established track record in drug development of novel cancer therapies and has strong experience with corporate strategy, business development and intellectual property matters. During his career Dr Hopkins has managed and overseen several strategic alliance and licensing deals with global pharmaceutical partners.
Most recently, he was the Chief Executive Officer of PharmAust Ltd, an ASX-listed biotechnology company. Prior to that, he was Managing Director at Phylogica Ltd, a company he co-founded in 2001 where he also held a variety of other positions including Chief Scientific Officer and Chief Operating Officer.
Richard holds a PhD in Molecular Biology, is an author on over 25 peer-reviewed publications and is an inventor on 17 patents and patent applications. Dr Hopkins currently serves as a member of the Western Australian Ausbiotech Committee.
CPA, CVA has experience in finance, marketing, business development, and operations primarily within the pharmaceutical industry. Lisa was a Co-founder, Vice Chair and CFO of Ilera Healthcare, a vertically integrated Grower, Processor and Dispenser of Medicinal Marijuana in Pennsylvania, sold to TerrAscend Corp in 2019. Lisa is a Co-founder and Vice Chair of Advanced Biomedics Holdings which founded a Grower and Processor in Louisiana, and Ilera Therapeutics LLC, acquired by Zelda Therapeutics also in 2019.
Lisa is also the Co-founder and Managing Partner of PIPV Capital, a Private Equity firm focused on building companies in life sciences, where she manages the financial aspects of the firm and portfolio, generates and leads investments, manages investor communications, and acts as Board Member CEO, CFO, and/or plays various management roles, as necessary, for portfolio companies. Lisa has previously served as COO for GlaxoSmithKline (“GSK”) Pharmaceuticals Ventures, a pharmaceutical venture fund, as well as other operations and transactions roles over 13 years with GSK. Prior to joining GSK, Lisa was a management consultant and auditor with Coopers & Lybrand. Ms. Gray holds a Bachelor of Science in Accountancy from Villanova University, an MBA in Finance from Penn State University, and a Post-Graduate Degree in Marketing Management. Lisa is also active in various community organizations and non-profits that positively impact people’s quality of life.
Managing Director USA
With over 10 years in corporate pharmaceutical business development, strategy & operational leadership, Dr. Odumosu brings a unique combination of experiences from academic, public health and life science organizations. In his role as Ilera Healthcare’s first Chief Operating Officer, Dr Odumosu was a core part of the executive team in establishing and managing Ilera’s business operation’s post license award in 2017 through to profitability.
He serves as Chief Scientific Officer/EVP Pharmaceutical Division for TerrAscend Corp. Prior to Ilera and Zelira, Dr. Odumosu played a critical role in Iroko Pharmaceutical’s post-clinical development of Zorvolex® Tivorbex® and Vivlodex® through FDA approvals and successful US market commercialization. He received a PhD in Biochemistry and a Master’s in Public Health-Epidemiology and Biostatistics from the Loma Linda University School of Medicine and School of Public Health in Loma Linda, California; and a BS in Biology from Calvin College in Grand Rapids, Michigan.
Dr. Odumosu is a World Bank Institute Certified public health professional with global healthcare translational/clinical/epidemiological research and data management experience.
Last updated 13th February 2020